Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study ; volume:19 ; number:1 ; day:12 ; month:9 ; year:2024 ; pages:1-10 ; date:12.2024
Addiction science & clinical practice ; 19, Heft 1 (12.9.2024), 1-10, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Stopka, Thomas J.
Rottapel, Rebecca
Friedmann, Peter D.
Pivovarova, Ekaterina
Evans, Elizabeth A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13722-024-00486-2
- URN
-
urn:nbn:de:101:1-2411262109275.347119177283
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Stopka, Thomas J.
- Rottapel, Rebecca
- Friedmann, Peter D.
- Pivovarova, Ekaterina
- Evans, Elizabeth A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables
Buprenorphine – The ideal drug for most clinical indications for an opioid?
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
Buprenorphine - the unique opioid analgesic : pharmacology and clinical application ; 13 tables